Erasca, Inc.

NasdaqGS:ERAS Stock Report

Market Cap: US$973.1m

Erasca Management

Management criteria checks 4/4

Erasca's CEO is Jonathan Lim, appointed in Jul 2018, has a tenure of 7.42 years. total yearly compensation is $3.89M, comprised of 16.6% salary and 83.4% bonuses, including company stock and options. directly owns 11.4% of the company’s shares, worth $110.98M. The average tenure of the management team and the board of directors is 4.3 years and 7.2 years respectively.

Key information

Jonathan Lim

Chief executive officer

US$3.9m

Total compensation

CEO salary percentage16.55%
CEO tenure7.4yrs
CEO ownership11.4%
Management average tenure4.3yrs
Board average tenure7.2yrs

Recent management updates

Recent updates

Erasca: Hype Building Into The End Of The Year (Rating Downgrade)

Oct 03

Erasca, Inc.: Carving A Different Niche In RAS Signaling

Apr 25

Erasca (NASDAQ:ERAS) Is In A Good Position To Deliver On Growth Plans

Feb 07
Erasca (NASDAQ:ERAS) Is In A Good Position To Deliver On Growth Plans

Erasca's Naporafenib Is Shaping Up Nicely For NRASm Melanoma

Jan 27

We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth

Oct 15
We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth

Erasca: New Focus After Restructuring, But Need More Differentiation

Sep 30

Is Erasca (NASDAQ:ERAS) In A Good Position To Deliver On Growth Plans?

Feb 21
Is Erasca (NASDAQ:ERAS) In A Good Position To Deliver On Growth Plans?

We Think Erasca (NASDAQ:ERAS) Needs To Drive Business Growth Carefully

Nov 16
We Think Erasca (NASDAQ:ERAS) Needs To Drive Business Growth Carefully

Companies Like Erasca (NASDAQ:ERAS) Are In A Position To Invest In Growth

Jun 28
Companies Like Erasca (NASDAQ:ERAS) Are In A Position To Invest In Growth

We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth

Jan 20
We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth

Erasca forms clinical trial partnership with Pfizer for cancer therapy

Oct 20

Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation

Sep 23
Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation

Erasca adds 10% ahead of R&D Day

Sep 07

Erasca, Eli Lilly to collaborate on trial to evaluate combo treatment for two cancers

Jul 18

We're Not Very Worried About Erasca's (NASDAQ:ERAS) Cash Burn Rate

Apr 12
We're Not Very Worried About Erasca's (NASDAQ:ERAS) Cash Burn Rate

Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation

Dec 28
Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation

CEO Compensation Analysis

How has Jonathan Lim's remuneration changed compared to Erasca's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$128m

Jun 30 2025n/an/a

-US$128m

Mar 31 2025n/an/a

-US$158m

Dec 31 2024US$4mUS$645k

-US$162m

Sep 30 2024n/an/a

-US$159m

Jun 30 2024n/an/a

-US$158m

Mar 31 2024n/an/a

-US$127m

Dec 31 2023US$5mUS$623k

-US$125m

Sep 30 2023n/an/a

-US$231m

Jun 30 2023n/an/a

-US$236m

Mar 31 2023n/an/a

-US$240m

Dec 31 2022US$8mUS$593k

-US$243m

Sep 30 2022n/an/a

-US$138m

Jun 30 2022n/an/a

-US$149m

Mar 31 2022n/an/a

-US$141m

Dec 31 2021US$850kUS$498k

-US$123m

Sep 30 2021n/an/a

-US$154m

Jun 30 2021n/an/a

-US$119m

Mar 31 2021n/an/a

-US$96m

Dec 31 2020US$2mUS$300k

-US$102m

Compensation vs Market: Jonathan's total compensation ($USD3.89M) is about average for companies of similar size in the US market ($USD3.47M).

Compensation vs Earnings: Jonathan's compensation has been consistent with company performance over the past year.

CEO

Jonathan Lim (53 yo)

7.4yrs
Tenure
US$3,894,032
Compensation

Dr. Jonathan E. Lim, M.D., is Independent Non-Employee Director of Maze Therapeutics, Inc. and was its Independent Director from October 2019. He Co-founded Erasca, Inc. in July 2018 and has been its Chair...

Leadership Team

NamePositionTenureCompensationOwnership
Jonathan Lim
Co-Founder7.4yrsUS$3.89m11.4%
$ 111.0m
David Chacko
CFO & Chief Business Officer5yrsUS$1.88m0.092%
$ 899.3k
Shannon Morris
Chief Medical Officer3.6yrsUS$1.59m0%
$ 0
Nik Chetwyn
Chief Operating Officer4.6yrsno datano data
Robert Shoemaker
Chief Scientific Officerless than a yearno datano data
Ebun Garner
General Counsel & Corporate Secretary4.7yrsUS$2.02m0.0075%
$ 72.6k
Lisa Tesvich-Bonora
Chief People Officer3.9yrsno datano data
Brian Baker
Senior Vice President of Finance4.6yrsno datano data
Chandra Lovejoy
Chief Regulatory Affairs Officer4.6yrsno datano data
Minli Xie
Senior Vice President of Pharmaceutical Development & Operations3.1yrsno datano data
Dawei Xuan
Senior Vice President of Clinical Pharmacology2.6yrsno datano data
Les Brail
Senior Vice President of Early Clinical Development2.6yrsno datano data
4.3yrs
Average Tenure
53yo
Average Age

Experienced Management: ERAS's management team is considered experienced (4.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jonathan Lim
Co-Founder7.2yrsUS$3.89m11.4%
$ 111.0m
George Demetri
Scientific Advisory Board Memberno datano datano data
Michael Varney
Chairman of Research & Development5.3yrsUS$175.46k0%
$ 0
Alexander Casdin
Independent Director7.4yrsUS$146.91k0.24%
$ 2.3m
Pratik Multani
Independent Director7.4yrsUS$134.70k0.061%
$ 592.9k
Kevan Shokat
Scientific Advisory Board Memberno datano datano data
James Bristol
Lead Independent Director7.5yrsUS$179.10k0.073%
$ 711.7k
Julie Hambleton
Independent Director4.8yrsUS$138.37k0.0021%
$ 20.5k
Ryan Corcoran
Scientific Advisory Board Memberno datano datano data
Valerie Harding-Start
Independent Director6.5yrsUS$144.69k0.0077%
$ 75.4k
Karen Cichowski
Scientific Advisory Board Memberno datano datano data
Pablo Rodriguez-Viciana
Scientific Advisory Board Memberno datano datano data
7.2yrs
Average Tenure
66yo
Average Age

Experienced Board: ERAS's board of directors are considered experienced (7.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/26 10:33
End of Day Share Price 2025/12/26 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Erasca, Inc. is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alec StranahanBofA Global Research
Naureen QuibriaCapital One Securities, Inc.
Chris ShibutaniGoldman Sachs